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\s=b\This study was designed to evaluate the impact of antihyper-
tensive therapy on cardiac dysrhythmias in 13 hypertensive pa-
tients who received calcium entry blockers and in 10 hyperten-
sive patients who received hydrochlorothiazide. Mean arterial
pressure fell to a similar extent in both treatment groups; howev-
er, left ventricular mass index decreased (from 102\m=+-\4to 95\m=+-\2
g/m2) only in patients receiving calcium entry blockers, but not in
those taking hydrochlorothiazide. The prevalence of premature
ventricular contractions decreased 74% from 21 14/h to
5.7 \m=+-\6/h in the calcium entry blocker group, but did not change in
the hydrochlorothiazide group (15\m=+-\17/h to 16\m=+-\13/h). Couplets,
multiform contractions, ventricular tachycardia, and supraven-
tricular tachycardia were completely abolished after calcium en-
try blocker therapy, whereas the prevalence of these arrhythmias
remained unchanged during treatment with hydrochlorothia-
zide. We conclude that antihypertensive therapy with calcium
entry blockers (but not with thiazide diuretics) reduces left ven-
tricular mass and the prevalence and severity of ventricular
dysrhythmias. Whether this reduction will improve the ominous
prognosis of left ventricular hypertrophy and diminish the risk of
sudden death remains unknown.
(Arch Intern Med. 1989;149:1263-1267)
f~^ alcium entry blockers have been proven to be effective and
safe agents in the treatment of coronary artery disease1'5
and essential hypertension." Calcium entry blockers not only
reduce arterial pressure levels by decreasing total peripheral
resistance, but may also be useful in allowing left ventricular
hypertrophy (LVH) to regress.6'13 Moreover, calcium entry
blockers have emerged as a new class of antiarrhythmic
agents,14 their most striking action being a prompt termina¬
tion of most supraventricular arrhythmias and some forms of
ventricular ones.14"21
For many years, thiazide diuretics have been used as first-
line agents in the stepped-care approach of antihypertensive
therapy.22,23 They are still used extensively because they are
inexpensive, effective, and well tolerated. However, concern
has been expressed that long-term thiazide diuretic therapy
may predispose to cardiac dysrhythmias.24"28 Also, some re¬
cent studies have shown that despite a reduction in arterial
pressure, LVH does not diminish when thiazide diuretics are
given.2"0
This study was designed to evaluate cardiac dysrhythmias
before and after effective antihypertensive therapy with calci¬
um entry blockers and with diuretics in a selected group of
hypertensive patients who had ambulatory electrocardio¬
graphic documentation ofventricular ectopy.
PATIENTS AND METHODS
The study population consisted of 23 patients with essential hyper¬
tension. Established essential hypertension was said to be present if
diastolic pressures measured in the outpatient clinic were consistent¬
ly higher than 90 mm Hg. All patients had appropriate clinical and
laboratory evaluation to exclude secondary forms of hypertension.
We also excluded patients with overt coronary artery disease or other
organic heart diseases as evidenced by clinical, electrocardiographic,
and echocardiographic criteria. Exercise treadmill testing was done
in some patients when clinically indicated.
In all patients who had been previously treated, antihypertensive
medication was discontinued at least 4 weeks before entry in the
study. Patients qualified for the study if they had any ventricular
dysrhythmias during 24-hour Holter monitoring and if their diastolic
pressure was equal to or greater than 90 mm Hg and less than 115 mm
Hg on at least two consecutive outpatient visits.
Ambulatory electrocardiographic monitoring (Del Mar Avionics)
was performed during a 24-hour period starting and ending at 9 am.
Each tape was initially scanned at high speed (Dynamic Electrocar-
dioscanner, model 655, Del Mar Avionics), and subsequently re¬
viewed for detailed analysis by two independent investigators who
were unaware of other study results at the time of the analysis. A
printout was obtained of the complete 24-hour recording. Left ven¬
tricular function and structure were assessed by M-mode echocardio¬
graphy (guided by two-dimensional echo). Measurements were ob¬
tained following the recommendations of the American Society of
Echocardiography.31 Left ventricular mass was calculated according
to the formula ofTroy et al32 and corrected by body surface area. Also,
a 12-lead electrocardiogram was recorded in all patients and blood
was drawn to measure serum electrolyte levels.
The therapeutic goal was to achieve diastolic pressure values equal
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Table 1 .—Arterial Pressure and Left Ventricular Function Before and After Therapy
With Calcium Entry Blockers and Hydrochlorothiazide
Calcium Entry Blockers Hydrochlorothiazide
Before After Before After
Systolic pressure, mm Hg
Diastolic pressure, mm Hg
Mean arterial pressure, mm Hg
Heart rate, bpmf
Ejection fraction, %
Fractional fiber shortening, %
165±6
90±2
116 + 2
76±8
73±2
37±4
132±4*
81+3*
98 ±3*
72±9
76±3
38±2
152±16
98 ±14
115±10
64 + 5.0
65 ±3.0
36 ±3.0
137 + 14*
86 ±9.2*
103 ±9.0*
63±12
67±10
38 ±7.0
*P<.001 (before and after antihypertensive therapy),
tbpm indicates beats per minute.
Table 2—Left Ventricular Structure Before and After Therapy With Calcium Entry Blockers and Hydrochlorothiazide
Calcium Entry Blocker Hydrochlorothiazide
Before After Before After
Septal wall thickness, cm
Posterior wall thickness, cm
Relative wall thickness
Left ventricular mass, g
Left ventricular mass index, g/m2
1.20 ±0.9
1.10±0.8
45 ± 1.2
200 ±7.0
102 ±4.0
1.18±0.7
1.0 + 0.3*
42±1.1*
175 ±4.0*
95 ±2.0*
1.33 ±0.34
1.12±0.21
42 ±6.8
290±115f
146 + 58
1.30 ±0.38
1.10 + 0.16
42 ±8.4
290±118t
146±60
*P<.05 (before and after antihypertensive therapy).
fP<05 (calcium entry blocker group vs hydrochlorothiazide group).
Table 3. —Prevalence of Cardiac Arrhythmias Before and After Therapy With Calcium Entry Blockers and Hydrochlorothiazide*
Calcium Entry Blockers, No. (%) Hydrochlorothiazide, No. (%)
Before After Before After
Simple PVCs
Coupled PVCs
Multiform PVCs
Ventricular tachycardia
Supraventricular tachycardia
13/13 (100)
7/13 (85)
5/13 (26)
4/13 (25)
4/13 (25)
5/13 (26)
0/13 (0)
0/13 (0)
0/13 (0)
0/13 (0)
10/10 (100)
7/10 (70)
8/10 (80)
4/10 (40)
5/10 (50)
10/10 (100)
9/10 (90)
10/10 (100)
3/10 (30)
5/10 (50)
*PVCs indicate premature ventricular contractions.
to or lower than 90 mm Hg. At the beginning of the active treatment
phase patients were seen weekly, and the dose of the antihyperten¬
sive agent was titrated to achieve an optimal response. Once diastolic
pressure was below 90 mm Hg, patients were followed up every 2
weeks. After the 8- to 12-week period of treatment each patient
underwent another complete physical examination, 24-hour Holter
monitoring, echocardiogram, and 12-lead electrocardiogram.
Calcium Entry Blocker Group
The calcium entry blocker group consisted of 13 men (12 white and 1
black), mean age, 48 ± 5 years, and mean body surface area, 1.86 ±0.7
m2. Seven patients had echocardiographic evidence of LVH,33 and
only three patients had electrocardiographic evidence of LVH. All
patients received calcium entry blockers for an 8-week period. Five
patients were given verapamil in the sustained release formulation(range, 120 to 480 mg/d); four patients, diltiazem (range, 60 to 480
mg/d); and four patients, isradipine (range, 5 to 15 mg/d).
Hydrochlorothiazide Group
The hydrochlorothiazide group consisted of 10 hypertensive pa¬
tients: 5 men and 5 women; 6 white and 4 black; mean age, 50 + 8
years; and mean body surface area, 1.90 ± 0.1 m2. Eight patients had
echocardiographic evidence of LVH, and six patients had electrocar¬
diographic evidence of LVH.3,1 All patients received hydrochlorothia¬
zide in doses ranging from 50 to 100 mg/d.
Statistical Methods
Analysis of variance with repeated measurements was used to
compare values before and after treatment. Statistical significance of
prevalence of ectopie beats as well as complex ventricular arrhyth¬
mias was evaluated by  2 analysis.34
CLINICAL FINDINGS
Systolic, diastolic, and mean arterial pressures were signif¬
icantly reduced by 10%, 12%, and 10%, respectively, after
treatment with calcium entry blockers and 11% change with
hydrochlorothiazide (Table 1), whereas heart rate, ejection
fraction, and fractional fiber shortening did not change in
either group (Table 1).
In the calcium entry blocker group, septal and posterior
wall thickness decreased; consequently, left ventricular mass
diminished by 13% and relative wall thickness by 7% (Table
2). In contrast, septal and posterior wall thickness, relative
wall thickness, and left ventricular mass did not change after
therapy with hydrochlorothiazide (Table 2).
Electrocardiographic time intervals P-R, QRS, QTc, and
ST, and serum electrolyte levels remained unchanged after
treatment in both groups. Serum potassium levels were
4.45 ±0.4 mmol/L before and 4.20 ±0.4 mmol/L after treat¬
ment in the hydrochlorothiazide group, and 4.09 ± 0.6 mmol/L
before and 4.33 ±0.5 mmol/L after treatment in the calcium
entry blocker group. Potassium supplements were given
when the serum potassium level fell below 3.5 mmol/L. Three
patients received potassium supplements at the time of the
second 24-hour Holter monitoring.
Prevalence and severity of ventricular ectopy were similar
Downloaded From: http://archinte.jamanetwork.com/ by a UQ Library User  on 09/15/2015
Calcium
Entry Blockade Diuretics
o
>
_
40
30-
20
10
0J
Before After Before After
Prevalence of premature ventricular contractions before and after
antihypertensive therapy with calcium entry blockade and diuretics,
respectively.
in the two groups before treatment (Table 3). The prevalence
of premature ventricular contractions decreased 74% from
21±14/h to 5.7±6/h (P<.001) in the calcium entry blocker
group, but did not change in the hydrochlorothiazide group(15 ± 17/h to 16 ± 13/h). Simple premature ventricular con¬
tractions were reduced by 74%, whereas couplets, multiform
premature ventricular contractions, and ventricular and su¬
praventricular tachycardias were completely suppressed
with calcium entry blocker treatment (Table 3; Figure). Ac¬
cordingly, patients treated with calcium entry blockers
scored significantly lower with regard to the Lown's classifi¬
cation when compared with pretreatment grades. In con¬
trast, neither the prevalence ofsimple premature ventricular
contractions nor more complex cardiac dysrhythmias
changed after hydrochlorothiazide treatment. Accordingly,
average Lown's classification of the patients remained un¬
changed after hydrochlorothiazide treatment.
COMMENT
Cardiac adaptation to a prolonged increase in arterial pres¬
sure results in LVH. However, LVH is not merely a physio¬
logic adaptive process serving to compensate for the in¬
creased afterload in essential hypertension.36 Data from the
Framingham cohort and later studies have clearly docu¬
mented that LVH is an important risk factor for the devel¬
opment of subsequent cardiovascular morbidity and mor¬
tality. aM8 Our group has shown that patients with concentric
LVH by electrocardiographic criteria have a higher preva¬
lence of premature ventricular contractions and more com¬
plex ventricular arrhythmias than patients without LVH or
normal subjects.39 Similarly, hypertensive patients with ec¬
centric LVH and isolated septal hypertrophy detected by
echocardiographic criteria also have a higher prevalence of
ventricular arrhythmias.™'41Our study indicates that short-term oral therapy with
calcium entry blockers lowered arterial pressure, reduced
left ventricular mass while preserving left ventricular func¬
tion, and, most importantly, reduced the prevalence of ven¬
tricular ectopie beats and more complex arrhythmias. In
contrast, although hydrochlorothiazide lowered arterial pres¬
sure to the same extent and maintained left ventricular func¬
tion similar to calcium entry blockers, it neither decreased left
ventricular mass nor reduced ventricular ectopy. Both of
these findings are in accord with previous clinical observa¬
tions.22·23·29'30'42·45
Calcium entry blockers (verapamil, diltiazem, and others)
have a well-established therapeutic role in the acute termina¬
tion of paroxysmal supraventricular tachycardia when given
intravenously and, when administered orally, can prevent its
recurrence. 15"19,4W9 In contrast, the effect of calcium entry
blockers on ventricular dysrhythmias is relatively ill de¬
fined. 14,20,21 There is no datum showing that calcium entry
blockers suppress ventricular ectopy in patients with chronic
ischemie heart disease or in patients with normal hearts.
Clinical experience suggests that calcium entry blockers have
little or no effect in patients with chronic ventricular ta-
chyarrhythmias or life-threatening ventricular arrhyth¬
mias38'50"52 (for a more comprehensive review, see reference
20). However, recent data indicate that the role of calcium
entry blockers can suppress exercise-induced tachycardia in
patients with coronary heart disease.52"54 Calcium entry
blockers have also been effective in treating ventricular
tachycardia occurring in young patients with otherwise nor¬
mal hearts.55"58 Given this knowledge, the suppression of su¬
praventricular tachycardia in our patients was no surprise.
Unexpected, however, was the 74% reduction of ventricular
ectopy and the complete suppression of ventricular couplets,
multiform ventricular contractions, and more complex ven¬
tricular arrhythmias.
The exact mechanism by which LVH triggers cardiac ar¬
rhythmias is not completely understood. Anatomic factors
such as enlarged myocytes, multiple intercalated disks, and
small areas of fibrosis have been proven to facilitate intercel¬
lular current flow, and hence, intercellular conduction, pro¬
ducing areas of reentry mechanisms.5"1 Mechanical factors
such as the stretching of isolated myocardial cells have been
shown to lower electric threshold amplitude and therefore
increase automaticity.62,63 Furthermore, hypertensive pa¬
tients with LVH are also at risk for subendocardial ischemia,
since myocardial oxygen demand often exceeds oxygen sup¬
ply, and coronary reserve is reduced.64*
Four pathophysiologic mechanisms singly or in combina¬
tion may account for the reduction of ventricular arrhythmias
associated with calcium entry blockers in our study popula¬
tion. A decrease in LVH may reverse some of the above
processes, at least as long as the left ventricle has not ex¬
ceeded a certain critical mass. Coronary vasodilatation and
the reduction in left ventricular mass may improve subendo¬
cardial ischemia9,64"69; although none of our patients had clini¬
cal, electrocardiographic, or other evidence of myocardial
ischemia, the possibility of microvascular disease™ or latent
ischemia cannot be ruled out. Calcium entry blockers may
exert a direct antiarrhythmic effect on the electrically irrita¬
ble myocardium.464771 Diuretic-induced electrolyte imbalance
may maintain or increase ventricular ectopy in diuretic-treat¬
ed patients, and, conversely, the increase in potassium after
calcium entry blockade may suppress ventricular ectopy.
Finally, a fall in arterial pressure (reduction of the hemody¬
namic burden) also reduces left ventricular wall stress and
stroke work, and therefore diminishes myocardial oxygen
demands. Sideris et al72 found an acute elevation of arterial
pressure with metaraminol therapy to induce premature ven¬
tricular contractions, whereas a reduction or disappearance
of ventricular ectopy occurred after arterial pressure was
lowered with nitroprusside therapy. However, the fact that
diuretic therapy reduced arterial pressure to the same extent
as therapy with calcium entry blockers, without improving
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ventricular ectopy, argues against this latter mechanism (a
reduction in arterial pressure) being the sole cause of the
decrease in ventricular dysrhythmias in our study.
Clearly, the conclusive power of this study is limited since it
was not done in a prospective double-blind randomized cross¬
over design. Also there were differences between the two
treatment groups with regard to race, gender, and preva¬
lence of LVH. Despite these potential drawbacks, our study
suggests that antihypertensive therapy with calcium entry
blockers, but not with thiazide diuretics, reduces ventricular
dysrhythmias. More studies involving larger numbers of pa¬
tients and other antihypertensive drugs without intrinsic
antiarrhythmic properties are needed to identify the exact
electrophysiologic mechanism of this observation. Whether
the decrease in left ventricular mass and suppression of ven¬
tricular ectopy associated with calcium entry blocker therapy
will improve the ominous prognosis of LVH, and ultimately
diminish the risk of sudden death, remains unknown.
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